Received U.S. Food and Drug Administration Orphan Drug Designation for Inspirex Lung and a $2.99 million National Institutes of Health grant to advance development of the investigational bioengineered lung graft.
XYLYX BIO develops bioengineered human organ grafts to increase transplantable organ supply. Advance life-saving transplantation with the Inspirex™ platform.